Pfizer Inc. (NYSE:PFE) announced today that it broke ground for a $95
million consumer products production facility in Suzhou, China. The new
site is near the company’s existing Suzhou site and will help increase
production capacity to meet growing demand for Pfizer Consumer
Healthcare’s brands in China and the Asia-Pacific region.
“Asia Pacific is a large and rapidly growing region for Pfizer Consumer
Healthcare and our new plant in Suzhou will give us the production
capacity we need to meet increasing demand for our brands, particularly
in China,” said Andy Schmeltz, Regional President, Asia Pacific and
Europe, Middle East and Africa, Pfizer Consumer Healthcare.
The new facility will primarily produce Caltrate® dietary supplements
and Centrum® multivitamins, and in the future will support production of
additional products. There are also plans to eventually house a research
and development facility on the site to help support innovation in the
region.
The site design is expected to achieve Leadership in Energy and
Environmental Design (LEED) certifications, and will incorporate the
most advanced technologies to minimize energy and water consumption.
For instance, to minimize energy consumption, the plant will be fitted
with high-efficiency manufacturing equipment, LED and solar powered
lighting with automatic controls. It will employ technologies to recycle
waste heating and cooling and will make extensive use of natural
lighting and shading. To conserve water, the plant will use high
efficiency equipment and fixtures, recycle treated wastewater for its
cooling tower and for toilets and capture rain water for irrigation of
its lawn and landscaping.
“This new site is the latest step on our journey of environmental
sustainability,” said Tony Maddaluna, Executive Vice President and
President of Pfizer Global Supply. “For 15 years, we have voluntarily
met or exceeded the public goals we have set to reduce our greenhouse
gas emissions globally. This new facility is in keeping with that
commitment to environmental stewardship.”
Pfizer in Suzhou
The Pfizer Suzhou facility began production in 1994, and since then has
implemented a number of expansion projects to keep pace with
double-digit growth in demand for Caltrate and Centrum. The existing
Suzhou facility employs about 700 colleagues, and produces Centrum
multivitamins, Caltrate dietary supplements, Robitussin® cough and cold
products, antibiotics as well as other prescription and over-the-counter
products. It supplies multiple countries in the Asia Pacific region,
including China.
“We are pleased to build on the strong foundation we have in Suzhou,
where we have produced consumer healthcare and prescription products for
more than twenty years,” said Keith Choy, Regional General Manager,
North Asia, Pfizer Consumer Healthcare. “We are confident that as we
expand with a new site here, we will build on the productive and
mutually beneficial relationships we have developed with the community.
Pfizer in China
Pfizer has been doing business in China since the 1980s and employs
approximately 10,000 colleagues there, with approximately 1,400 working
in Pfizer Consumer Healthcare. Currently, Pfizer operates in 300 cities
throughout China, has three other production facilities in the country
in addition to its operations in Suzhou, and operates two world-class
research and development centers in China. To learn more, please visit www.pfizer.com.cn.
Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world's
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world's
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, Pfizer has worked to make a difference for all who
rely on us. To learn more, please visit us at www.pfizer.com.
DISCLOSURE NOTICE: The information contained in this release is as of
June 15, 2015. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new information or
future events or developments.
This release contains forward-looking information related to the
development of a new production facility in China by Pfizer, including
Pfizer’s plans and prospects for the production facility and its
potential benefits, that involves substantial risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied by such statements. Risks and uncertainties
include, among other things, risks related to the timely completion of
the production facility or at all; risks related to the ability to
realize the anticipated benefits of the production facility, including
the possibility that the expected benefits from the proposed production
facility will not be realized or will not be realized within the
expected time period; other business effects, including the effects of
industry, market, economic, political or regulatory conditions; future
exchange or interest rates; and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2014 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results”, as well as in
its subsequent reports on Form 8-K, all of which are filed with the SEC
and available at www.sec.gov
and www.pfizer.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150615005638/en/
Copyright Business Wire 2015